The the0 retical advantages of supervoltage roentgentherapy can only be assessed by results obtained from clinical use. Although the first supervoltage units were first used clinically more than 25 years ago, there is a scarcity of quantitative clinical data that demonstrates the superiority of supervoltage roentgentherapy in any group of cancer patients (2, 3, 4, 5, 13, 14, 23, 24, 25, 26, 27). The term supervoltage must be clearly defined. Teleradium units that contain 5 to 10 grams of radium are not considered supervoltage equipment. The wave length o f the rays emitted must be augmented by other physical factors that include a long source-skin distance (SSD) to produce beams similar to those of the million volt X-ray generators which, in comparison with orthovoltage radiation, are characterized by : 1. Skin-sparing. This is a result of the phenomenon of electronic build-up below the surface of the skin. 2. An increase in depth dose. 3. Enhancement of systemic and organ tolerance. Tolerance is enhanced because less energy is absorbed, for the same tumor dose, by the surrounding structures and the body. 4. A decrease in bone absorption. This is advantageous when bone must be traversed because the tissue doses are the same values obtained form depth dose tables, whereas with 3-1 mm. Cu HVL beam, tissue doses may be 10 to 20 per cent less than the values of the depth dose tables. The million volt X-ray generators, linear accelerators, betatrons and kilocurie cobalt-60 units produce beams which fulfill these four criteria. The hectocurie cobalt60 units and, less so, the cesium-137 units are not comparable to supervoltage equipment in all respects. The depth doses are comparable to those of 3-5 mm. Cu half-value layer (HVL) beams with focal-skin distance (FSD) of 50 to 70 centimeters.
Read full abstract